BTS
CLVS

BB&T Securities’s Clovis Oncology, Inc. CLVS Stock Holding History

BB&T Securities’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,925
Closed -$207K – 1611
2018
Q1 		$207K Sell
3,925
-100
-2% -$5.83K ﹤0.01% 1397
2017
Q4 		$273K Buy
4,025
+525
+15% +$36.7K ﹤0.01% 1226
2017
Q3 		$288K Buy
+3,500
New +$277K ﹤0.01% 1177

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return

BB&T Securities's CLVS Position: Q2 2018 in Review

BB&T Securities sold out of Clovis Oncology, Inc. (CLVS) in Q2 2018, closing a stake of 3,925 shares — an estimated $207K sold.

BB&T Securities first reported a position in CLVS in Q3 2017 and held it in 3 quarters. The position peaked at $288K in Q3 2017. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

  • BB&T Securities reported no remaining Clovis Oncology, Inc. position as of Q2 2018 after selling out during the quarter.
  • BB&T Securities sold 3,925 Clovis Oncology, Inc. shares in Q2 2018, an estimated $207K.
  • BB&T Securities first reported a position in Clovis Oncology, Inc. in Q3 2017 and held it in 3 quarters.
  • BB&T Securities's Clovis Oncology, Inc. position peaked at $288K in Q3 2017.
  • 210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on BB&T Securities's 13F filing for Q2 2018, filed 13 Aug 2018.